-+ 0.00%
-+ 0.00%
-+ 0.00%
Kang Stem Biotech Expects KRW 3 Billion Payment Under Knee Osteoarthritis Treatment License Deal
Share
Listen to the news
Kang Stem Biotech Expects KRW 3 Billion Payment Under Knee Osteoarthritis Treatment License Deal
  • Kang Stem Biotech expects KRW 3 billion in second-stage royalties from Yooyoung Pharmaceutical under its OSCA knee osteoarthritis treatment license agreement.
  • The November 7, 2024, agreement required payment upon selection of a domestic co-developer or by end-2026, whichever came first.
  • Written confirmation that payment conditions were met arrived November 17, 2026; payments will be split into KRW 1 billion installments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kang Stem Biotech Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261117900329), on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending